Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C J Rodenburg

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Breast Cancer Research and Treatment|January 1, 1992
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancerM Bontenbal, A S Planting, C J Rodenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot studyM E van der Burg, S C Henzen-Logmans, J A Foekens, et al.
Scandinavian Journal of Haematology|January 1, 1985
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphomaR Willemze, W G Peters, M B van Hennik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumoursC R Lewis, S D Fossà, G Mead, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 13, 2007
[Mucocutaneous manifestations of amyloidosis]L Timmer-de Mik, R I F van der Waal, M R Canninga-van Dijk, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical studyS C Henzen-Logmans, M E van der Burg, J A Foekens, et al.
Journal of Neurology|June 1, 1994
The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trialJ M van Gerven, A Hovestadt, J W Moll, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicityJ Tol, M Koopman, C J Rodenburg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2006
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III studyM Koopman, N F Antonini, J Douma, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancerJ A Foekens, W L van Putten, H Portengen, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Breast Cancer Research and Treatment|January 1, 1992
Weekly low-dose mitoxantrone plus doxorubicin as second-line chemotherapy for advanced breast cancerM Bontenbal, A S Planting, C J Rodenburg, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
The prognostic value of epidermal growth factor receptors, determined by both immunohistochemistry and ligand binding assays, in primary epithelial ovarian cancer: a pilot studyM E van der Burg, S C Henzen-Logmans, J A Foekens, et al.
Scandinavian Journal of Haematology|January 1, 1985
Intermediate and high-dose ARA-C and m-AMSA (or daunorubicin) as remission and consolidation treatment for patients with relapsed acute leukaemia and lymphoblastic non-Hodgkin lymphomaR Willemze, W G Peters, M B van Hennik, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 1, 1991
BOP/VIP--a new platinum-intensive chemotherapy regimen for poor prognosis germ cell tumoursC R Lewis, S D Fossà, G Mead, et al.
Nederlands Tijdschrift Voor Geneeskunde|October 13, 2007
[Mucocutaneous manifestations of amyloidosis]L Timmer-de Mik, R I F van der Waal, M R Canninga-van Dijk, et al.
Journal of Cancer Research and Clinical Oncology|January 1, 1992
Occurrence of epidermal growth factor receptors in benign and malignant ovarian tumors and normal ovarian tissues: an immunohistochemical studyS C Henzen-Logmans, M E van der Burg, J A Foekens, et al.
Journal of Neurology|June 1, 1994
The effects of an ACTH (4-9) analogue on development of cisplatin neuropathy in testicular cancer: a randomized trialJ M van Gerven, A Hovestadt, J W Moll, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 15, 2008
A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicityJ Tol, M Koopman, C J Rodenburg, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2006
Randomised study of sequential versus combination chemotherapy with capecitabine, irinotecan and oxaliplatin in advanced colorectal cancer, an interim safety analysis. A Dutch Colorectal Cancer Group (DCCG) phase III studyM Koopman, N F Antonini, J Douma, et al.
The Journal of Steroid Biochemistry and Molecular Biology|December 20, 1990
Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancerJ A Foekens, W L van Putten, H Portengen, et al.
Pageof 5